Expert Pearls
A
| B
| C
| D
| E
| F
| G
| H
| I
| J
| K
| L
| M
| N
| O
| P
| Q
| R
| S
| T
| U
| V
| W
| X
| Y
| Z
| 0-9
|
Hepatitis C - Glycyrrhizin I.V. Glycyrrhizin I.V. with an average dose of 100 mL 3 times a week (usual dose: 40ml to 100ml once daily, 3-5 times a week) reduced the incidence of HCC from interferon resistant hepatitis C patients. [Hepatol Res, 2007 Sept;37 Suppl 2:S287-93. 46248 (8/2008)] Summary Interview |
| Vitamin K2 45 mg/d reduced the incidence of hepatic carcinoma in patients with viral cirrhosis. [Hepatol Res. 2007 Sep;37 Suppl 2:S303-7. 46249 (4/2008)] Summary Interview |
| Vitamin K2 45 mg/d reduced the incidence of hepatic carcinoma in patients with viral cirrhosis. [JAMA, July 21, 2004;292 (3):358-361. 41865 (10/2004)] Summary Interview |
| Zinc (polaprezinc) 150 mg/d (33.9 mg elemental zinc) in two divided doses after breakfast and before bed along with vitamin C 600 mg/d and vitamin E 300 mg/d, and, combination therapy with pegylated interferon alpha-2b and ribavirin decreased serum ALT levels to within the normal range, decreased plasma TBARS and prevented a decrease in PUFA on the erythrocyte membrane indicating that polaprezinc had induced antioxidative functions in the liver resulting in reduced hepatocyte injury. [J Nutr Sci Vitaminol (Tokyo), 2007; 53(3): 213-8. 45690 (1/2008)] Summary Interview |
| Zinc sulphate 300 mg/d in chronic hepatitis C on a-interferon therapy. [Biol Trace Element Res, 1997;58:65-76. 28702 (1998)] Summary Interview |
| Powered by Sigsiu.NET |  |
